Answers are grounded in this paper and cite their sources.
Fluoropyrimidines, principally 5-fluorouracil (5-FU) and capecitabine, remain foundational agents in the treatment of gastrointestinal, breast, and head and neck malignancies, but they are also among the most clinically important non-anthracycline causes of cancer therapy-related cardiovascular toxicity. Clinical manifestations range from asymptomatic electrocardiographic abnormalities and biomarker elevation to angina, coronary vasospasm, myocardial infarction, arrhythmias, heart failure, Takotsubo syndrome, and sudden cardiac death. Although coronary vasospasm remains the most recognized mechanism, contemporary evidence supports a multifactorial pathophysiology involving endothelial dysfunction, oxidative stress, direct myocardial injury, mitochondrial dysfunction, thrombosis, and microvascular dysfunction. The reported incidence varies widely because of differences in definitions, surveillance intensity, cancer populations, and fluoropyrimidine schedules. Management begins with immediate discontinuation of fluoropyrimidine and evaluation for acute coronary syndrome or other cardiac emergencies. A major unresolved question is whether fluoropyrimidine therapy can be safely resumed after cardiotoxicity. Older reports suggested high recurrence rates with rechallenge, whereas more recent cardio-oncology-guided series suggest that selected patients may successfully continue treatment using vasodilator prophylaxis, regimen modification, and close monitoring. This narrative review summarizes the epidemiology, mechanisms, clinical manifestations, diagnosis, acute management, rechallenge strategies, and alternatives to fluoropyrimidines when re-exposure is unsafe.
No takes yet. Share an insight, caveat, or question.
Peshin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: